Ani9, A Novel Potent Small-Molecule ANO1 Inhibitor with Negligible Effect on ANO2

Area of Science:

• Molecular Biology
• Pharmacology
• Ion Channel Research

Background:

• Anoctamin1 (ANO1)/transmembrane protein 16A (TMEM16A) is a calcium-activated chloride channel (CaCC) crucial for physiological processes.
• Existing ANO1 inhibitors lack potency and selectivity, hindering research and therapeutic development.
• ANO1 plays roles in fluid secretion, muscle contraction, pain, and cancer progression.

Purpose of the Study:

• To identify highly potent and selective small molecule inhibitors of ANO1.
• To characterize the novel inhibitors discovered through high-throughput screening.
• To evaluate the potential of these inhibitors as pharmacological tools and therapeutic candidates.

Main Methods:

• High-throughput screening of 54,400 synthetic small molecules.
• Electrophysiological analysis to assess ANO1 channel activity and inhibition.
• Selectivity assays comparing ANO1 inhibition versus ANO2 and effects on CFTR and intracellular calcium.

Main Results:

• Three novel ANO1 inhibitors were identified, blocking channel activity with IC50 < 3 μM.
• The most potent inhibitor, Ani9, demonstrated submicromolar potency and high selectivity for ANO1 over ANO2.
• Ani9 did not impact intracellular calcium signaling or CFTR chloride channel activity.

Conclusions:

• Ani9 is a highly potent and selective small molecule inhibitor of ANO1.
• Ani9 serves as a valuable pharmacological tool for ANO1 research.
• Ani9 holds potential for therapeutic development in conditions like cancer, hypertension, pain, diarrhea, and asthma.